Innovation Pharmaceuticals Inc (IPIX)

[steelyeye]

This post should be stickied... excellent job CMC!

some excerpts follow, but the whole post should be read.

Tecovirimat is also a good example of what happens after NIAID takes a drug successfully to a Phase 2A. The company that owns the drug completes the rest of the development through FDA approval/authorization.

In the case of B-AV, Leo will be in the driver's seat, not only because "B" will have the data. thanks to NIAID. but also because the potential partner will know that after a successful Phase 3 and FDA approval/authorization: the U.S. gov't, as well as other gov'ts will be the first customers in line placing orders in the hundreds of millions for B-AV (broad spectrum), B-COVID, Monkeypox or any other family of viruses that threaten the U.S. and other populations around the world.

It is very important that NIAID has latched onto Brilacidin and after 2.5 years is still investigating the scope of its antiviral attributes. NIAID's is responsible for finding and initially developing vaccines and therapeutics that address viral pathogens that are threatening or could threaten the U.S. population. NIAID is the playmaker, who coordinates and collaborates with other similarly concerned U.S. gov't agencies and gov't-funded, private research institutions.

NIAID has a high-degree of interest in Brilacidin and I can't wait to see which direction they move in. Will it be "B" as a COVID prophylactic, broad-spectrum antiviral or possibly something involving mokeypox?

One thing's for sure, the antiviral sector is Brilacidin's most lucrative area ($67B) and IPIX is in collaboration with an agency of the U.S. government (NIAID) that is extremely interested in investigating "B" ,as an antiviral, for all that it can do. AT NO CHARGE TO IPIX.